First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial

Yelena Y. Janjigian, Steven B. Maron, Walid K. Chatila, Brittanie M Millang, Shweta S. Chavan, Carly Alterman, Joanne F. Chou, Michal Segal, Marc Simmons, Parisa Momtaz, Marina Shcherba, Geoffrey Y. Ku, Alice Zervoudakis, Elizabeth Won, David P. Kelsen, David H. Ilson, Rebecca J. Nagy, Richard B. Lanman, Ryan Ptashkin, Mark T.A. Donoghue, Marinela Capanu, Barry S. Taylor, David B. Solit, Nikolaus Schultz, Jaclyn F. Hechtman